TY - JOUR
T1 - Continuous versus Intermittent Midazolam Sedation in Balloon-Assisted Enteroscopy
T2 - A Multicenter Randomized Trial
AU - Sakakibara, Yuko
AU - Mannami, Tomohiko
AU - Kuwai, Toshio
AU - Kagaya, Takashi
AU - Toyokawa, Tatsuya
AU - Katsushima, Shinji
AU - Kanda, Toshihiro
AU - Shimada, Masaaki
AU - Kuramochi, Mizuki
AU - Hamada, Shohei
AU - Fujii, Hiroyuki
AU - Watanabe, Noriko
AU - Wakatsuki, Toshiyuki
AU - Tamaru, Yuzuru
AU - Esaka, Naoki
AU - Sasaki, Yoshihiro
AU - Kubo, Kimitoshi
AU - Mabe, Katsuhiro
AU - Yamada, Takuya
AU - Ishihara, Akio
AU - Uraoka, Toshio
AU - Kato, Mototsugu
AU - Kada, Akiko
AU - Saito, Akiko M.
AU - Harada, Naohiko
N1 - Publisher Copyright:
© 2026 The Author(s). Published by S. Karger AG, Basel
PY - 2026
Y1 - 2026
N2 - Introduction: Sedation protocols for balloon-assisted enteroscopy (BAE) are not yet standardized. The aim of this study was to compare the efficacy and safety between continuous infusion and intermittent bolus administration of midazolam for sedation during BAE. The study hypothesis was that continuous infusion would provide a greater proportion of time under conscious sedation than would intermittent bolus administration. Methods: We conducted a multicenter, prospective, double-blind, randomized controlled trial at 15 institutions of the National Hospital Organization in Japan. Patients scheduled for diagnostic or therapeutic BAE were randomly assigned to receive continuous infusion or intermittent bolus administration of intravenous midazolam. The primary endpoint was the proportion of time under conscious sedation, defined as a Ramsay Sedation Scale score of 3–4. Secondary endpoints included body movements causing procedure interruption, endoscopist and patient satisfaction, total drug dosage, adverse events, and termination of the procedure. Results: Of 76 enrolled patients (39 continuous infusion group, 37 intermittent bolus group), one from each group discontinued before treatment, leaving 74 patients (38 continuous group, 36 intermittent bolus group) for analysis. The proportion of time under conscious sedation was comparable between groups (mean ± SD: 0.637 ± 0.315 vs. 0.609 ± 0.272, p = 0.721). However, the continuous infusion group showed a lower incidence of body movements causing procedure interruption (7.9% vs. 25.0%, p = 0.091). The total midazolam dose was higher in the continuous infusion group, whereas the incidence of adverse events was comparable between the two groups. Conclusion: Continuous infusion of midazolam did not demonstrate superiority over intermittent bolus administration with regard to the proportion of time under conscious sedation. However, continuous infusion suppressed body movements during BAE without increasing adverse events; thus, it could be one of the feasible sedation options for BAE in clinical practice.
AB - Introduction: Sedation protocols for balloon-assisted enteroscopy (BAE) are not yet standardized. The aim of this study was to compare the efficacy and safety between continuous infusion and intermittent bolus administration of midazolam for sedation during BAE. The study hypothesis was that continuous infusion would provide a greater proportion of time under conscious sedation than would intermittent bolus administration. Methods: We conducted a multicenter, prospective, double-blind, randomized controlled trial at 15 institutions of the National Hospital Organization in Japan. Patients scheduled for diagnostic or therapeutic BAE were randomly assigned to receive continuous infusion or intermittent bolus administration of intravenous midazolam. The primary endpoint was the proportion of time under conscious sedation, defined as a Ramsay Sedation Scale score of 3–4. Secondary endpoints included body movements causing procedure interruption, endoscopist and patient satisfaction, total drug dosage, adverse events, and termination of the procedure. Results: Of 76 enrolled patients (39 continuous infusion group, 37 intermittent bolus group), one from each group discontinued before treatment, leaving 74 patients (38 continuous group, 36 intermittent bolus group) for analysis. The proportion of time under conscious sedation was comparable between groups (mean ± SD: 0.637 ± 0.315 vs. 0.609 ± 0.272, p = 0.721). However, the continuous infusion group showed a lower incidence of body movements causing procedure interruption (7.9% vs. 25.0%, p = 0.091). The total midazolam dose was higher in the continuous infusion group, whereas the incidence of adverse events was comparable between the two groups. Conclusion: Continuous infusion of midazolam did not demonstrate superiority over intermittent bolus administration with regard to the proportion of time under conscious sedation. However, continuous infusion suppressed body movements during BAE without increasing adverse events; thus, it could be one of the feasible sedation options for BAE in clinical practice.
KW - Analgesics
KW - Anesthesia
KW - Conscious sedation
KW - Double-balloon endoscopy
KW - Single-balloon endoscopy
UR - https://www.scopus.com/pages/publications/105035592567
UR - https://www.scopus.com/pages/publications/105035592567#tab=citedBy
U2 - 10.1159/000550292
DO - 10.1159/000550292
M3 - Article
C2 - 41493892
AN - SCOPUS:105035592567
SN - 0012-2823
SP - 1
EP - 13
JO - Digestion
JF - Digestion
ER -